Expression-based drug screening of neural progenitor cells from individuals with schizophrenia

Benjamin Readhead, Brigham J. Hartley, Brian J. Eastwood, David A. Collier, David Evans, Richard Farias, Ching He, Gabriel Hoffman, Pamela Sklar, Joel T. Dudley, Eric E. Schadt, Radoslav Savić, Kristen J. Brennand

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

A lack of biologically relevant screening models hinders the discovery of better treatments for schizophrenia (SZ) and other neuropsychiatric disorders. Here we compare the transcriptional responses of 8 commonly used cancer cell lines (CCLs) directly with that of human induced pluripotent stem cell (hiPSC)-derived neural progenitor cells (NPCs) from 12 individuals with SZ and 12 controls across 135 drugs, generating 4320 unique drug-response transcriptional signatures. We identify those drugs that reverse post-mortem SZ-associated transcriptomic signatures, several of which also differentially regulate neuropsychiatric disease-associated genes in a cell type (hiPSC NPC vs. CCL) and/or a diagnosis (SZ vs. control)-dependent manner. Overall, we describe a proof-of-concept application of transcriptomic drug screening to hiPSC-based models, demonstrating that the drug-induced gene expression differences observed with patient-derived hiPSC NPCs are enriched for SZ biology, thereby revealing a major advantage of incorporating cell type and patient-specific platforms in drug discovery.

Original languageEnglish (US)
Article number4412
JournalNature Communications
Volume9
Issue number1
DOIs
StatePublished - Dec 1 2018

Fingerprint

schizophrenia
Preclinical Drug Evaluations
Induced Pluripotent Stem Cells
Schizophrenia
Screening
Stem cells
drugs
Stem Cells
screening
stem cells
cells
Pharmaceutical Preparations
cultured cells
Cell Line
cancer
signatures
Drug Discovery
Gene expression
gene expression
Neoplasms

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

Readhead, B., Hartley, B. J., Eastwood, B. J., Collier, D. A., Evans, D., Farias, R., ... Brennand, K. J. (2018). Expression-based drug screening of neural progenitor cells from individuals with schizophrenia. Nature Communications, 9(1), [4412]. https://doi.org/10.1038/s41467-018-06515-4

Expression-based drug screening of neural progenitor cells from individuals with schizophrenia. / Readhead, Benjamin; Hartley, Brigham J.; Eastwood, Brian J.; Collier, David A.; Evans, David; Farias, Richard; He, Ching; Hoffman, Gabriel; Sklar, Pamela; Dudley, Joel T.; Schadt, Eric E.; Savić, Radoslav; Brennand, Kristen J.

In: Nature Communications, Vol. 9, No. 1, 4412, 01.12.2018.

Research output: Contribution to journalArticle

Readhead, B, Hartley, BJ, Eastwood, BJ, Collier, DA, Evans, D, Farias, R, He, C, Hoffman, G, Sklar, P, Dudley, JT, Schadt, EE, Savić, R & Brennand, KJ 2018, 'Expression-based drug screening of neural progenitor cells from individuals with schizophrenia', Nature Communications, vol. 9, no. 1, 4412. https://doi.org/10.1038/s41467-018-06515-4
Readhead, Benjamin ; Hartley, Brigham J. ; Eastwood, Brian J. ; Collier, David A. ; Evans, David ; Farias, Richard ; He, Ching ; Hoffman, Gabriel ; Sklar, Pamela ; Dudley, Joel T. ; Schadt, Eric E. ; Savić, Radoslav ; Brennand, Kristen J. / Expression-based drug screening of neural progenitor cells from individuals with schizophrenia. In: Nature Communications. 2018 ; Vol. 9, No. 1.
@article{9d52f748de4642b1aa6392d94d1ef5ab,
title = "Expression-based drug screening of neural progenitor cells from individuals with schizophrenia",
abstract = "A lack of biologically relevant screening models hinders the discovery of better treatments for schizophrenia (SZ) and other neuropsychiatric disorders. Here we compare the transcriptional responses of 8 commonly used cancer cell lines (CCLs) directly with that of human induced pluripotent stem cell (hiPSC)-derived neural progenitor cells (NPCs) from 12 individuals with SZ and 12 controls across 135 drugs, generating 4320 unique drug-response transcriptional signatures. We identify those drugs that reverse post-mortem SZ-associated transcriptomic signatures, several of which also differentially regulate neuropsychiatric disease-associated genes in a cell type (hiPSC NPC vs. CCL) and/or a diagnosis (SZ vs. control)-dependent manner. Overall, we describe a proof-of-concept application of transcriptomic drug screening to hiPSC-based models, demonstrating that the drug-induced gene expression differences observed with patient-derived hiPSC NPCs are enriched for SZ biology, thereby revealing a major advantage of incorporating cell type and patient-specific platforms in drug discovery.",
author = "Benjamin Readhead and Hartley, {Brigham J.} and Eastwood, {Brian J.} and Collier, {David A.} and David Evans and Richard Farias and Ching He and Gabriel Hoffman and Pamela Sklar and Dudley, {Joel T.} and Schadt, {Eric E.} and Radoslav Savić and Brennand, {Kristen J.}",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41467-018-06515-4",
language = "English (US)",
volume = "9",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Expression-based drug screening of neural progenitor cells from individuals with schizophrenia

AU - Readhead, Benjamin

AU - Hartley, Brigham J.

AU - Eastwood, Brian J.

AU - Collier, David A.

AU - Evans, David

AU - Farias, Richard

AU - He, Ching

AU - Hoffman, Gabriel

AU - Sklar, Pamela

AU - Dudley, Joel T.

AU - Schadt, Eric E.

AU - Savić, Radoslav

AU - Brennand, Kristen J.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - A lack of biologically relevant screening models hinders the discovery of better treatments for schizophrenia (SZ) and other neuropsychiatric disorders. Here we compare the transcriptional responses of 8 commonly used cancer cell lines (CCLs) directly with that of human induced pluripotent stem cell (hiPSC)-derived neural progenitor cells (NPCs) from 12 individuals with SZ and 12 controls across 135 drugs, generating 4320 unique drug-response transcriptional signatures. We identify those drugs that reverse post-mortem SZ-associated transcriptomic signatures, several of which also differentially regulate neuropsychiatric disease-associated genes in a cell type (hiPSC NPC vs. CCL) and/or a diagnosis (SZ vs. control)-dependent manner. Overall, we describe a proof-of-concept application of transcriptomic drug screening to hiPSC-based models, demonstrating that the drug-induced gene expression differences observed with patient-derived hiPSC NPCs are enriched for SZ biology, thereby revealing a major advantage of incorporating cell type and patient-specific platforms in drug discovery.

AB - A lack of biologically relevant screening models hinders the discovery of better treatments for schizophrenia (SZ) and other neuropsychiatric disorders. Here we compare the transcriptional responses of 8 commonly used cancer cell lines (CCLs) directly with that of human induced pluripotent stem cell (hiPSC)-derived neural progenitor cells (NPCs) from 12 individuals with SZ and 12 controls across 135 drugs, generating 4320 unique drug-response transcriptional signatures. We identify those drugs that reverse post-mortem SZ-associated transcriptomic signatures, several of which also differentially regulate neuropsychiatric disease-associated genes in a cell type (hiPSC NPC vs. CCL) and/or a diagnosis (SZ vs. control)-dependent manner. Overall, we describe a proof-of-concept application of transcriptomic drug screening to hiPSC-based models, demonstrating that the drug-induced gene expression differences observed with patient-derived hiPSC NPCs are enriched for SZ biology, thereby revealing a major advantage of incorporating cell type and patient-specific platforms in drug discovery.

UR - http://www.scopus.com/inward/record.url?scp=85055465084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055465084&partnerID=8YFLogxK

U2 - 10.1038/s41467-018-06515-4

DO - 10.1038/s41467-018-06515-4

M3 - Article

C2 - 30356048

AN - SCOPUS:85055465084

VL - 9

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 4412

ER -